NeuroSense Therapeutics Ltd. (NASDAQ:NRSN) Financings
Financings
| Raise | Date |
|---|---|
| Private placement of ordinary shares Announced: US$600,000 · US$0.8 a share Buyers: Alon Ben-Noon ($200,000); Or Eisenberg ($200,000) Insiders: CEO Alon Ben-Noon and CFO Or Eisenberg each committed $200,000 Use of proceeds: General corporate purposes ahead of upcoming clinical and regulatory milestones | Apr 28, 2026 |
| Private placement of ordinary shares Announced: US$500,000 · US$1.5 a share Use of proceeds: General corporate purposes and working capital | Sep 4, 2025 |
| Private placement of ordinary shares (or ordinary share equivalents) and warrants Closed: US$5M raised · US$1.25 a share · Warrants at US$1.25 for 60 months Buyers: Alon Ben-Noon Insiders: Chief Executive Officer Alon Ben-Noon entered into the definitive agreement to purchase in the private placement alongside a single investor Use of proceeds: General corporate and working capital purposes | Dec 18, 2024 |